About XenoPort
XenoPort is a company based in Santa Clara (United States) founded in 1999 was acquired by Arbor pharma in May 2016.. XenoPort has raised $100.9 million across 7 funding rounds from investors including Orbimed, Arch Venture Partners and The Michael J. Fox Foundation. The company has 156 employees as of December 31, 2022. XenoPort offers products and services including Slot Games Platform and Gaming App. XenoPort operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Santa Clara, United States
- Employees 156 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$100.9 M (USD)
in 7 rounds
-
Latest Funding Round
$20 M (USD), Series E
Nov 19, 2012
-
Investors
Orbimed
& 14 more
-
Employee Count
156
as on Dec 31, 2022
-
Acquired by
Arbor pharma
(May 23, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of XenoPort
XenoPort offers a comprehensive portfolio of products and services, including Slot Games Platform and Gaming App. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for playing various slot games online
App for accessing and playing slot games
Unlock access to complete
Unlock access to complete
Funding Insights of XenoPort
XenoPort has successfully raised a total of $100.9M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $20 million completed in November 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series E — $20.0M
-
First Round
First Round
(03 Jun 2002)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2012 | Amount | Series E - XenoPort | Valuation |
investors |
|
| Jul, 2012 | Amount | Grant - XenoPort | Valuation |
investors |
|
| Nov, 2010 | Amount | Grant - XenoPort | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in XenoPort
XenoPort has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Arch Venture Partners and The Michael J. Fox Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by XenoPort
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - XenoPort
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xenoport Comparisons
Competitors of XenoPort
XenoPort operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about XenoPort
When was XenoPort founded?
XenoPort was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Where is XenoPort located?
XenoPort is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Is XenoPort a funded company?
XenoPort is a funded company, having raised a total of $100.9M across 7 funding rounds to date. The company's 1st funding round was a Grant of $194K, raised on Jun 03, 2002.
How many employees does XenoPort have?
As of Dec 31, 2022, the latest employee count at XenoPort is 156.
What does XenoPort do?
XenoPort is developing and commercializing a portfolio of internally discovered product candidates for neurological disorders. Provides treatment for Restless Leg Syndrome (RLS) and Post-Herpetic Neuralgia (PHN). Offers two products - Horizant (gabapentin enacarbil, Extended-Release Tablets approved for the USA) and Regnite (gabapentin enacarbil Extended-Release Tablets approved for Japan and marketed by Astellas Pharma). XenoPort claims to hold all other world-wide rights to gabapentin enacarbil. The pipeline includes potential treatments for patients with Parkinsons disease (XP21279), relapsing-remitting multiple sclerosis and psoriasis (XP23829), and Alcohol Use Disorder (Arbaclofen Placabil).
Who are the top competitors of XenoPort?
XenoPort's top competitors include Jazz Pharmaceuticals, Flexion Therapeutics and PTC Therapeutics.
What products or services does XenoPort offer?
XenoPort offers Slot Games Platform and Gaming App.
Who are XenoPort's investors?
XenoPort has 15 investors. Key investors include Orbimed, Arch Venture Partners, The Michael J. Fox Foundation, Arbor pharma, and HBM Healthcare Investments.